查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2098442

嗜睡症治療市場－全球預測，2026-2032年

Narcolepsy Drugs Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，嗜睡症治療市場將成長至 55.7 億美元，複合年成長率為 6.79%。

主要市場統計數據
基準年 2025 35.1億美元
預計年份：2026年 37.6億美元
預測年份 2032 55.7億美元
複合年成長率 (%) 6.79%

發作性睡病的治療在睡眠醫學中佔據著重要的臨床地位，主要針對1型和2型發作性睡病相關的白天過度嗜睡、猝倒、夜間睡眠障礙、睡眠癱瘓和入睡幻覺等症狀。治療方法包括促醒劑、興奮劑、氧合鈉製劑、組織胺H3受體反向促效劑、用於控制猝倒的抗憂鬱症。發作性睡病治療的需求不斷成長，這主要源於人們對中樞性嗜睡症認知的提高、多導睡眠睡眠多項生理檢查和多次睡眠潛伏期測試等診斷方法的更新，以及對生活品質下降、職業安全、駕駛風險、心血管代謝問題和合併精神健康問題的日益關注。主要醫療保健系統的監管機構持續強調隨機試驗的證據、上市後安全監測、管制藥物的安全措施、懷孕和兒童安全注意事項以及適當的風險評估項目。發作性睡病治療市場的主題包括發作性睡病治療、治療白天過度嗜睡的藥物、猝倒症治療、羥考酮類藥物、清醒增強劑、睡眠障礙藥物、嗜睡症治療和精準睡眠醫學。

嗜睡症治療領域的變革性變化

發作性睡病的治療趨勢正從症狀性覺醒管理轉向更個人化、基於機制的治療。在臨床實務中，治療方案的選擇越來越精細化，取決於患者對症狀群、心血管風險、精神疾病史、藥物使用、兒童和成人用藥差異、懷孕計畫、合併用藥以及給藥方案的偏好。每日一次（睡前服用）的羥考酮和低鈉製劑正在改變人們對藥物依從性的討論，尤其對於那些擔心夜間用藥負擔和鈉攝入量的患者而言。同時，組織胺能和多巴胺能覺醒路徑仍然是治療研發的核心，臨床醫生需要在療效與失眠、焦慮、血壓升高、潛在濫用和藥物交互作用等風險之間取得平衡。此外，隨著睡眠中心整合遠端醫療分診、穿戴式睡眠數據、標準化睡眠記錄、腕動計和合併症篩檢，診斷方法也不斷發展，以減少轉診延誤，並改善睡眠多項生理檢查和多階段睡眠潛伏期測試適應症的選擇。由於保險公司的審查、管制藥品的配藥要求以及對真實世界數據的期望，製藥公司和醫療保健提供者必須證明其產品對日常生活功能、工作效率、學業成績、駕駛安全、治療連續性和長期耐受性具有可衡量的影響。

人工智慧對嗜睡症治療發展帶來的累積影響

人工智慧正開始對發作性睡病的治療產生影響，涵蓋藥物發現、診斷、臨床開發和患者管理等各個面向。在藥物發現方面，機器學習可用於幫助確定與Orexin訊號傳導、組織胺調節、多巴胺-去甲腎上腺素路徑以及睡眠-覺醒迴路相關的標靶優先級，同時還能改善化合物的藥物動力學和安全性篩檢。在臨床實踐中，人工智慧驅動的睡眠多項生理檢查、腕動計、睡眠日記和患者自述結果分析，有助於早期識別白天過度嗜睡的模式，並減少睡眠測試結果解讀的差異。在臨床試驗中，人工智慧可以根據症狀嚴重程度、合併症情況、用藥史和用藥依從性來改善患者分層，而數位化終點指標可以比間歇性住院更持續地監測嗜睡、警覺性、夜間睡眠障礙和功能性結局。這些協同效應將加速向精準睡眠治療的過渡，但其實施需要演算法檢驗、透明的資料管治、減少偏差、與臨床系統互通性，以及遵守有關醫療設備和健康資料的法規。人工智慧最大的價值不在於取代檢驗的診斷標準，而在於輔助專家的判斷。

區域內關於獲得和引入嗜睡症治療的關鍵見解

隨著日本、中國、韓國、澳洲和印度不斷加強睡眠醫學體系，亞太地區在取得發作性睡病治療的重要性日益凸顯。然而，診斷不足仍然是一個長期存在的障礙，因為症狀常常被誤診為生活方式因素、憂鬱症、癲癇、阻塞型睡眠呼吸中止症或注意力缺陷障礙。在北美，儘管已通過核准的發作性睡病治療方案的引入取得了進展，但仍需要建立完善的睡眠檢測機構網路、藥物監管監測、患者權益倡導組織和保險報銷機制來支持患者獲得治療，同時還需要對診斷和治療效果進行充分的記錄。在拉丁美洲，都市區的臨床意識正在提高，巴西和墨西哥在擴大專科醫療服務方面發揮關鍵作用，但經濟負擔、睡眠檢測機構分佈不均以及保險報銷體系的碎片化仍然影響著治療模式。在歐洲，儘管已經建立了睡眠學會、藥物安全監測系統、孤兒藥和專科藥物評估框架以及跨境臨床指南，但各國報銷體系的差異仍然影響著患者獲得新療法的機會。在中東，神經科主導的三級醫療機構和睡眠醫學服務正在不斷發展，尤其是在高所得醫療體系中。然而，由於對睡眠障礙的文化認知不足以及專科醫生數量有限，可能導致診斷延遲。在非洲，睡眠醫學基礎設施仍然有限，導致診斷率偏低。因此，教育、轉診網路、必要的診斷工具以及獲得合適的藥物是發作性睡病管理的重中之重。

區域性對嗜睡症治療政策和取得途徑的關鍵見解。

在東南亞國協，隨著主要城市醫院擴大神經科、精神科和呼吸/睡眠醫學服務，人們對發作性睡病的認知正在逐步提高，但公立和私立醫療系統在獲得先進診斷和專科藥物方面的可及性存在顯著差異。海灣合作理事會（GCC）國家受益於對三級醫療、數位醫療基礎設施和專科醫生培訓的投資，提高了及時診斷和系統治療的可能性，但長期可及性取決於醫保覆蓋藥物清單的確定、轉診途徑以及臨床醫生的認知水平。歐盟擁有相對統一的法規環境和嚴格的藥物安全監測要求，但各成員國的醫保報銷和醫療技術評估結果存在差異，影響了新型發作性睡病療法的可及性。在金磚國家，可近性情況各不相同。中國和印度正迅速擴展其專科醫療體系，巴西正在都市區建立睡眠中心，俄羅斯擁有神經科專家，但就診管道較為分散，南非的臨床認知水平有所提高，但面臨基礎設施方面的限制。七國集團（G7）國家通常在已通過核准、睡眠研究活動、患者支持系統和循證處方方面發揮著主導作用，並在製定嗜睡症藥物的安全性、臨床終點和治療效果的全球標準方面具有重大影響力。北約成員國與歐洲和北美的先進醫療保健系統有相當大的重疊，在這些地區，軍事戰備、駕駛安全、職業表現和受監管藥物的管理日益受到重視，因此，有效管理白天過度嗜睡症也日益受到管治。

來自影響嗜睡症藥物使用情況的關鍵國家的見解

美國擁有最完善的嗜睡症治療體系之一，專科醫生普遍認可，藥物治療方案眾多且獲批，並設有監管完善的藥品分發項目，保險公司通常要求提供客觀的診斷證據。在加拿大，專科醫師主導的治療與省級醫保報銷體系相結合，能否獲得治療取決於是否被納入醫保覆蓋範圍以及是否有完整的臨床記錄。在墨西哥，主要城市的公眾意識正在提高，但自付費用和睡眠檢查室的可及性仍然存在差異，這仍然是實際面臨的挑戰。在巴西，睡眠醫學界十分活躍，人們對嗜睡症的認知也不斷提高，但地區差異影響診斷和治療的連續性。在英國，實證睡眠醫學治療路徑透過專科中心實施，而就診途徑則受國家指引和當地轉診系統的影響。德國、法國、義大利和西班牙擁有完善的神經病學和睡眠醫學網路、嚴格的藥物安全監測要求以及評估臨床療效的醫保報銷體系，其中德國和法國對歐洲專科醫療保健的評估具有重要影響。在俄羅斯，儘管神經病學和睡眠障礙領域擁有豐富的臨床經驗，但獲得新型嗜睡症治療的機會可能受到監管、採購和報銷條件的影響。在中國，隨著大規模醫院系統和數位醫療的引入，睡眠障礙的診斷正在擴大，但主要城市以外的認知水平仍然較低。在印度，由於專科醫生數量有限以及與其他醫療保健優先事項的競爭，漏診是一個嚴重的問題，儘管私立醫院和學術機構的認知水平正在提高。日本在嗜睡症和睡眠研究方面擁有多年的臨床經驗、完善的系統性法律規範體係以及較高的專科醫生認知水平。澳洲透過睡眠中心和轉診系統支援診斷，但保險報銷決定會影響患者的就醫。韓國正透過三級醫療機構、數位醫療的應用以及對白天過度嗜睡作為一種可治療的神經系統疾病的日益重視，推進睡眠醫學的發展。

為嗜睡症治療行業的領導者提供的實用建議

產業領導者應優先研發臨床差異化的發作性睡病治療方案，以解決白天過度嗜睡、猝倒、夜間睡眠障礙和功能障礙等問題，同時提高耐受性、用藥依從性和實際生活功能。研發策略應納入患者報告結局、警覺性數位化測量、長期安全性監測，並針對心血管疾病、精神疾病、兒童、懷孕相關疾病和老年患者等次族群進行分析。醫學教育應著重於幫助基層醫療、精神科、神經神經科、呼吸系統醫療設備、小兒科和職業健康專業人員區分發作性睡病與失眠、憂鬱症、癲癇、睡眠剝奪、晝夜節律紊亂和阻塞型睡眠呼吸中止症症，從而減少診斷延遲。藥物取得策略應符合管制藥品法規、保險報銷的證據要求、各國特定的處方限制以及強制性藥物安全監測要求。製藥公司和醫療保健相關人員應支援收集註冊登記資料、上市後安全性研究資料和真實世界資料（REW），以評估藥物的安全性、依從性、停藥因素、藥物交互作用和功能性結局。與睡眠中心、數位醫療服務提供者、學術機構和患者團體合作，可以改善服務不足地區的篩檢、轉診、治療連續性和公平性。

獲取有關嗜睡症治療的實證知識的調查方法

本執行摘要採用系統的二手研究方法編寫，參考了監管文件、臨床實踐指南、同行評審的睡眠醫學文獻、藥物安全監測資訊、公共衛生資料以及權威醫學會出版刊物等檢驗資訊來源。該調查方法強調對臨床證據、監管環境、治療類別特徵、診斷標準、報銷檢驗、安全標籤以及當地醫療保健基礎設施進行多方面研究途徑。篩選標準優先考慮已通過核准且指南引用的發作性睡病治療、日間過度嗜睡的管理、猝倒症治療、安全監測、管制藥物管理、臨床實踐中的治療障礙以及已記錄的醫療服務獲取差異等數據。本分析排除了檢驗的說法、宣傳標語、市場規模估算、市場佔有率和預測。區域和國家層面的洞察是透過醫療保健服務取得、睡眠檢查室可用性、專科醫生密度、報銷方案、管制藥物政策和監管成熟度等方面的差異來解讀的。目標是提供基於證據的說明，以支持策略決策，而不依賴推測性的市場估算和預測。

關於嗜睡症治療創新未來發展的結論

發作性睡病的治療正從傳統的症狀治療發展到更個人化、以療效為導向的睡眠障礙護理。這項創新得益於對睡眠和覺醒神經生物學更深入的理解、數位健康工具的廣泛應用、患者對便捷用藥的需求以及對長期安全性證據日益成長的期望。區域差異依然顯著，醫療體系發達的地區受益於成熟的診斷和報銷機制，而新興地區則致力於提高公眾意識、確保專科醫生資源、提供診斷途徑並減輕經濟負擔。人工智慧、真實世界數據和精準醫療方法，若在嚴格的檢驗和符合倫理的數據管治下實施，可望提升診斷水平、最佳化臨床試驗設計並改進治療方案選擇。對於參與發作性睡病治療的相關人員，最重要的優先事項是早期診斷、藥物差異化、公平取得、有效的安全監測以及患者功能狀態的顯著改善。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 嗜睡症治療市場：依藥物類別分類

  • 安非他命鹽
  • Modafinil衍生物
    • Modafinil
    • Modafinil
  • 新藥
    • 皮特里桑
    • 索利亞姆佩托爾
  • 羥丁酸鈉

第8章 嗜睡症治療市場：依疾病類型分類

  • 1型嗜睡症
  • 2型嗜睡症
  • 續發性嗜睡症

第9章：嗜睡症治療市場：依病患小組分類

  • 成人
  • 青年
  • 兒童
  • 老年人

第10章：嗜睡症治療市場：依作用機制分類

  • 多巴胺調節
  • Orexin激活
  • 血清素調節
  • GABA活化
  • 組織胺調節

第11章 嗜睡症治療市場：依劑型分類

  • 藥片
  • 膠囊
  • 液體
  • 注射藥物

第12章：嗜睡症治療市場：依通路分類

  • 線上
  • 離線

第13章 嗜睡症治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 嗜睡症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：嗜睡症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Alkermes plc
  • Amneal Pharmaceuticals, Inc.
  • Aurobindo Pharma Limited
  • Avadel Pharmaceuticals plc
  • Axsome Therapeutics, Inc.
  • BIOPROJET SCR
  • Cadila Pharmaceuticals Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • Glenmark Pharmaceuticals Limited
  • Harmony Biosciences Holdings, Inc.
  • Hikma Pharmaceuticals PLC
  • Jazz Pharmaceuticals plc
  • Lupin Limited
  • NLS Pharmaceutics Ltd.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Shionogi & Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma, Inc.
  • Viatris Inc.
  • Zevra Therapeutics, Inc.

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 嗜睡症治療市場：依藥物類別分類

  • 安非他命鹽
  • Modafinil衍生物
    • Modafinil
    • Modafinil
  • 新藥
    • 皮特里桑
    • 索利亞姆佩托爾
  • 羥丁酸鈉

第8章 嗜睡症治療市場：依疾病類型分類

  • 1型嗜睡症
  • 2型嗜睡症
  • 續發性嗜睡症

第9章：嗜睡症治療市場：依病患小組分類

  • 成人
  • 青年
  • 兒童
  • 老年人

第10章：嗜睡症治療市場：依作用機制分類

  • 多巴胺調節
  • Orexin激活
  • 血清素調節
  • GABA活化
  • 組織胺調節

第11章 嗜睡症治療市場：依劑型分類

  • 藥片
  • 膠囊
  • 液體
  • 注射藥物

第12章：嗜睡症治療市場：依通路分類

  • 線上
  • 離線

第13章 嗜睡症治療市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第14章 嗜睡症治療市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：嗜睡症治療市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Alkermes plc
  • Amneal Pharmaceuticals, Inc.
  • Aurobindo Pharma Limited
  • Avadel Pharmaceuticals plc
  • Axsome Therapeutics, Inc.
  • BIOPROJET SCR
  • Cadila Pharmaceuticals Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories Limited
  • Eli Lilly and Company
  • Glenmark Pharmaceuticals Limited
  • Harmony Biosciences Holdings, Inc.
  • Hikma Pharmaceuticals PLC
  • Jazz Pharmaceuticals plc
  • Lupin Limited
  • NLS Pharmaceutics Ltd.
  • Novartis AG
  • Otsuka Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Shionogi & Co., Ltd.
  • Sun Pharmaceutical Industries Limited
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Theravance Biopharma, Inc.
  • Viatris Inc.
  • Zevra Therapeutics, Inc.
Product Code: MRR-62667ADF9625

The Narcolepsy Drugs Market is projected to grow by USD 5.57 billion at a CAGR of 6.79% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.51 billion
Estimated Year [2026] USD 3.76 billion
Forecast Year [2032] USD 5.57 billion
CAGR (%) 6.79%

Narcolepsy drugs occupy a clinically important segment of sleep medicine, addressing excessive daytime sleepiness, cataplexy, disrupted nighttime sleep, sleep paralysis, and hypnagogic hallucinations associated with narcolepsy type 1 and type 2. The treatment landscape includes wake-promoting agents, stimulants, sodium oxybate formulations, histamine H3 receptor inverse agonists, and antidepressants used for cataplexy management. Demand is shaped by improved recognition of central disorders of hypersomnolence, updated diagnostic pathways using polysomnography and multiple sleep latency testing, and growing attention to quality-of-life impairment, occupational safety, driving risk, cardiometabolic considerations, and psychiatric comorbidity. Regulatory agencies in major healthcare systems continue to emphasize evidence from randomized trials, post-marketing safety surveillance, controlled-substance safeguards, pregnancy and pediatric safety considerations, and risk evaluation programs where appropriate. Themes defining the narcolepsy drugs market include narcolepsy treatment, excessive daytime sleepiness medication, cataplexy therapy, oxybate drugs, wake-promoting drugs, sleep disorder therapeutics, hypersomnolence treatment, and precision sleep medicine.

Transformative Shifts in the Narcolepsy Drugs Landscape

The narcolepsy drugs landscape is shifting from symptomatic wakefulness management toward more individualized, mechanism-driven care. Clinical practice increasingly differentiates treatment selection by symptom cluster, cardiovascular risk, psychiatric history, substance-use considerations, pediatric versus adult use, pregnancy planning, concomitant medications, and patient preference regarding dosing schedules. Once-nightly and lower-sodium oxybate formulations are changing adherence discussions, particularly for patients concerned about nighttime dosing burden or sodium exposure. At the same time, histaminergic and dopaminergic wake-promoting pathways remain central to treatment development as clinicians balance efficacy with risks such as insomnia, anxiety, blood pressure elevation, abuse potential, and drug interactions. Diagnosis is also evolving as sleep centers integrate telehealth triage, wearable sleep data, standardized sleep logs, actigraphy, and comorbidity screening to reduce delays in referral and improve selection for polysomnography and multiple sleep latency testing. Payer scrutiny, controlled-drug dispensing requirements, and real-world evidence expectations are encouraging manufacturers and healthcare providers to demonstrate measurable benefits in daily functioning, work productivity, school performance, driving safety, treatment persistence, and long-term tolerability.

Cumulative Impact of Artificial Intelligence on Narcolepsy Drug Development

Artificial intelligence is beginning to influence narcolepsy care across discovery, diagnosis, clinical development, and patient management. In drug discovery, machine learning can help prioritize targets involved in orexin signaling, histamine regulation, dopamine and norepinephrine pathways, and sleep-wake circuitry while improving the screening of compounds for pharmacokinetic and safety profiles. In clinical practice, AI-enabled analysis of polysomnography, actigraphy, sleep diaries, and patient-reported outcomes may support earlier identification of excessive daytime sleepiness patterns and reduce variability in sleep study interpretation. In clinical trials, AI can improve patient stratification by symptom severity, comorbidity profiles, medication history, and adherence behavior, while digital endpoints can capture sleepiness, alertness, nocturnal disruption, and functional outcomes more continuously than episodic clinic visits. The cumulative impact is a move toward precision sleep therapeutics; however, adoption depends on algorithm validation, transparent data governance, bias reduction, interoperability with clinical systems, and compliance with medical device and health data regulations. AI is most valuable when it augments specialist judgment rather than replacing validated diagnostic standards.

Key Regional Insights Across Narcolepsy Drug Access and Adoption

Asia-Pacific is gaining relevance in narcolepsy drug access as Japan, China, South Korea, Australia, and India strengthen sleep medicine capabilities, though underdiagnosis remains a persistent barrier because symptoms are often misattributed to lifestyle, depression, epilepsy, obstructive sleep apnea, or attention disorders. North America demonstrates advanced adoption of approved narcolepsy medications, structured sleep-lab networks, controlled-substance monitoring, patient advocacy, and reimbursement pathways that support access while requiring robust documentation of diagnosis and treatment response. Latin America shows rising clinical awareness in urban centers, with Brazil and Mexico playing important roles in specialist care expansion, but affordability, uneven sleep-lab availability, and fragmented reimbursement continue to shape treatment patterns. Europe benefits from established sleep societies, pharmacovigilance systems, orphan and specialty medicine assessment frameworks, and cross-country clinical guidelines, although national reimbursement variation influences access to newer therapies. The Middle East is expanding tertiary care and neurology-led sleep services, particularly in higher-income health systems, while cultural perceptions of sleep symptoms and limited specialist density can delay diagnosis. Africa remains characterized by limited sleep medicine infrastructure and low documented diagnosis rates, making education, referral networks, essential diagnostics, and access to appropriate medications central priorities for narcolepsy management.

Key Group Insights for Narcolepsy Drug Policy and Access

ASEAN countries are seeing gradual improvement in narcolepsy recognition as metropolitan hospitals expand neurology, psychiatry, and respiratory sleep services, yet access to advanced diagnostics and specialty drugs differs substantially between public and private systems. The GCC benefits from investment in tertiary hospitals, digital health infrastructure, and specialist training, supporting greater potential for timely diagnosis and structured treatment, although long-term access depends on formulary decisions, referral pathways, and clinician awareness. The European Union offers a relatively harmonized regulatory environment and strong pharmacovigilance expectations, but reimbursement and health technology assessment outcomes vary by member state, affecting availability of newer narcolepsy therapies. BRICS countries represent diverse access realities: China and India are expanding specialist capacity rapidly, Brazil has established urban sleep centers, Russia has neurological expertise but variable access pathways, and South Africa faces infrastructure constraints alongside growing clinical awareness. G7 countries generally lead in approved therapy availability, sleep research activity, patient support systems, and evidence-based prescribing, making them influential in shaping global standards for narcolepsy drug safety, clinical endpoints, and outcomes. NATO member countries overlap significantly with advanced European and North American healthcare systems, where military readiness, driving safety, occupational performance, and controlled-medication governance heighten attention to effective excessive daytime sleepiness management.

Key Country Insights Shaping Narcolepsy Drug Utilization

The United States has one of the most developed narcolepsy treatment ecosystems, with broad specialist awareness, multiple approved pharmacologic options, controlled dispensing programs, and payer requirements that often demand objective diagnostic evidence. Canada combines specialist-led care with provincial reimbursement variation, making access dependent on formulary status and clinical documentation. Mexico is experiencing rising awareness in major cities, though out-of-pocket costs and uneven sleep-lab access remain practical challenges. Brazil has an active sleep medicine community and growing recognition of hypersomnolence disorders, but regional disparities influence diagnosis and therapy continuity. The United Kingdom applies evidence-based sleep medicine pathways through specialist centers, with access shaped by national guidance and local commissioning. Germany, France, Italy, and Spain maintain established neurology and sleep medicine networks, strong pharmacovigilance expectations, and reimbursement systems that evaluate clinical benefit, while Germany and France are particularly influential in European specialty medicine assessment. Russia has clinical expertise in neurology and sleep disorders, although access to newer narcolepsy drugs can be affected by regulatory, procurement, and reimbursement conditions. China is expanding sleep disorder diagnosis through large hospital systems and digital health adoption, but awareness outside major cities is still developing. India faces substantial underdiagnosis due to limited specialist density and competing healthcare priorities, yet private hospitals and academic centers are improving recognition. Japan has long-standing clinical experience with narcolepsy and sleep research, with structured regulatory oversight and high awareness among specialists. Australia supports diagnosis through sleep centers and specialist referral pathways, with reimbursement decisions influencing patient access. South Korea is advancing sleep medicine through tertiary hospitals, digital health capabilities, and increasing awareness of excessive daytime sleepiness as a treatable neurological condition.

Actionable Recommendations for Narcolepsy Drug Industry Leaders

Industry leaders should prioritize clinically differentiated narcolepsy drugs that address excessive daytime sleepiness, cataplexy, disrupted nighttime sleep, and functional impairment while improving tolerability, adherence, and real-world functioning. Development strategies should incorporate patient-reported outcomes, digital measures of alertness, long-term safety monitoring, and subgroup analyses for cardiovascular, psychiatric, pediatric, pregnancy-related, and older adult populations. Medical education should focus on reducing diagnostic delay by helping primary care, psychiatry, neurology, pulmonology, pediatrics, and occupational health professionals distinguish narcolepsy from insomnia, depression, epilepsy, sleep deprivation, circadian rhythm disorders, and obstructive sleep apnea. Access strategies should align with controlled-substance regulations, reimbursement evidence requirements, country-specific prescribing restrictions, and pharmacovigilance obligations. Manufacturers and healthcare stakeholders should support registries, post-authorization safety studies, and real-world evidence generation to evaluate safety, adherence, discontinuation drivers, drug interactions, and functional outcomes. Partnerships with sleep centers, digital health providers, academic groups, and patient organizations can improve screening, referral, treatment persistence, and equity in underserved regions.

Research Methodology for Evidence-Based Narcolepsy Drug Insights

This executive summary is developed through a structured secondary research approach using verified sources such as regulatory agency documents, clinical practice guidelines, peer-reviewed sleep medicine literature, pharmacovigilance communications, public health resources, and recognized medical society publications. The methodology emphasizes triangulation across clinical evidence, regulatory status, therapeutic class characteristics, diagnostic standards, reimbursement considerations, safety labeling, and regional healthcare infrastructure. Inclusion criteria prioritize data related to approved and guideline-referenced narcolepsy therapies, excessive daytime sleepiness management, cataplexy treatment, safety monitoring, controlled-substance governance, real-world treatment barriers, and documented access differences. The analysis avoids unverified claims, promotional statements, market sizing, market share, and forecasting. Regional and country insights are interpreted through documented differences in healthcare access, sleep-lab availability, specialist density, reimbursement systems, controlled medication policies, and regulatory maturity. The objective is to provide an evidence-based, narrative that supports strategic decision-making without relying on speculative market estimates.

Conclusion on the Future of Narcolepsy Drug Innovation

Narcolepsy drugs are advancing from conventional symptomatic treatment toward more personalized, outcomes-oriented sleep disorder care. Innovation is being shaped by improved understanding of sleep-wake neurobiology, expanding use of digital health tools, patient demand for convenient dosing, and stronger expectations for long-term safety evidence. Regional disparities remain significant, with advanced healthcare systems benefiting from established diagnostic and reimbursement structures while emerging regions focus on awareness, specialist capacity, diagnostic access, and affordability. Artificial intelligence, real-world evidence, and precision medicine approaches are likely to strengthen diagnosis, clinical trial design, and therapy selection when implemented with rigorous validation and ethical data governance. For stakeholders in narcolepsy therapeutics, the most important priorities are earlier diagnosis, differentiated drug profiles, equitable access, robust safety surveillance, and measurable improvement in patient functioning.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Narcolepsy Drugs Market, by Drug Class

  • 7.1. Introduction
  • 7.2. Amphetamine Salts
  • 7.3. Modafinil Derivatives
    • 7.3.1. Armodafinil
    • 7.3.2. Modafinil
  • 7.4. Novel Agents
    • 7.4.1. Pitolisant
    • 7.4.2. Solriamfetol
  • 7.5. Sodium Oxybate

8. Narcolepsy Drugs Market, by Disease Type

  • 8.1. Introduction
  • 8.2. Narcolepsy Type 1
  • 8.3. Narcolepsy Type 2
  • 8.4. Secondary Narcolepsy

9. Narcolepsy Drugs Market, by Patient Group

  • 9.1. Introduction
  • 9.2. Adults
  • 9.3. Teenagers
  • 9.4. Children
  • 9.5. Elderly

10. Narcolepsy Drugs Market, by Mechanism of Action

  • 10.1. Introduction
  • 10.2. Dopamine Regulation
  • 10.3. Orexin Activation
  • 10.4. Serotonin Modulation
  • 10.5. GABA Activation
  • 10.6. Histamine Regulation

11. Narcolepsy Drugs Market, by Formulation

  • 11.1. Introduction
  • 11.2. Tablets
  • 11.3. Capsules
  • 11.4. Liquids
  • 11.5. Injectables

12. Narcolepsy Drugs Market, by Distribution Channel

  • 12.1. Introduction
  • 12.2. Online
  • 12.3. Offline

13. Narcolepsy Drugs Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. North America
  • 13.3. Latin America
  • 13.4. Europe
  • 13.5. Middle East
  • 13.6. Africa

14. Narcolepsy Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Narcolepsy Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Alkermes plc
  • 17.2. Amneal Pharmaceuticals, Inc.
  • 17.3. Aurobindo Pharma Limited
  • 17.4. Avadel Pharmaceuticals plc
  • 17.5. Axsome Therapeutics, Inc.
  • 17.6. BIOPROJET SCR
  • 17.7. Cadila Pharmaceuticals Limited
  • 17.8. Cipla Limited
  • 17.9. Dr. Reddy's Laboratories Limited
  • 17.10. Eli Lilly and Company
  • 17.11. Glenmark Pharmaceuticals Limited
  • 17.12. Harmony Biosciences Holdings, Inc.
  • 17.13. Hikma Pharmaceuticals PLC
  • 17.14. Jazz Pharmaceuticals plc
  • 17.15. Lupin Limited
  • 17.16. NLS Pharmaceutics Ltd.
  • 17.17. Novartis AG
  • 17.18. Otsuka Pharmaceutical Co., Ltd.
  • 17.19. Pfizer Inc.
  • 17.20. Shionogi & Co., Ltd.
  • 17.21. Sun Pharmaceutical Industries Limited
  • 17.22. Takeda Pharmaceutical Company Limited
  • 17.23. Teva Pharmaceutical Industries Ltd.
  • 17.24. Theravance Biopharma, Inc.
  • 17.25. Viatris Inc.
  • 17.26. Zevra Therapeutics, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL NARCOLEPSY DRUGS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL NARCOLEPSY DRUGS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL NARCOLEPSY DRUGS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL NARCOLEPSY DRUGS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL NARCOLEPSY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL NARCOLEPSY DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL NARCOLEPSY DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AMPHETAMINE SALTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AMPHETAMINE SALTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AMPHETAMINE SALTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL MODAFINIL DERIVATIVES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL MODAFINIL DERIVATIVES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL MODAFINIL DERIVATIVES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ARMODAFINIL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ARMODAFINIL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ARMODAFINIL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL MODAFINIL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL MODAFINIL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL MODAFINIL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NOVEL AGENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NOVEL AGENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NOVEL AGENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PITOLISANT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PITOLISANT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PITOLISANT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL SOLRIAMFETOL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL SOLRIAMFETOL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL SOLRIAMFETOL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL SODIUM OXYBATE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL SODIUM OXYBATE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL SODIUM OXYBATE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NARCOLEPSY TYPE 1 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NARCOLEPSY TYPE 1 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NARCOLEPSY TYPE 1 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NARCOLEPSY TYPE 2 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NARCOLEPSY TYPE 2 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NARCOLEPSY TYPE 2 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL SECONDARY NARCOLEPSY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL SECONDARY NARCOLEPSY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL SECONDARY NARCOLEPSY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ADULTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ADULTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ADULTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TEENAGERS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TEENAGERS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TEENAGERS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL CHILDREN MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL CHILDREN MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL CHILDREN MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ELDERLY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ELDERLY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ELDERLY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DOPAMINE REGULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DOPAMINE REGULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DOPAMINE REGULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL OREXIN ACTIVATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL OREXIN ACTIVATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL OREXIN ACTIVATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL SEROTONIN MODULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL SEROTONIN MODULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL SEROTONIN MODULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL GABA ACTIVATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL GABA ACTIVATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL GABA ACTIVATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HISTAMINE REGULATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HISTAMINE REGULATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HISTAMINE REGULATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TABLETS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TABLETS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TABLETS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CAPSULES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL CAPSULES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL CAPSULES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LIQUIDS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LIQUIDS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LIQUIDS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL INJECTABLES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL INJECTABLES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ONLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ONLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ONLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL OFFLINE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL OFFLINE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL OFFLINE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE NARCOLEPSY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. MIDDLE EAST NARCOLEPSY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 125. MIDDLE EAST NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. MIDDLE EAST NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 127. MIDDLE EAST NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 128. MIDDLE EAST NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. MIDDLE EAST NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 130. MIDDLE EAST NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 131. MIDDLE EAST NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 132. MIDDLE EAST NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 136. AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 137. AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 139. AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 140. AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 141. AFRICA NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 142. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN NARCOLEPSY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 146. ASEAN NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 147. ASEAN NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. ASEAN NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 149. ASEAN NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 150. ASEAN NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 151. ASEAN NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. GCC NARCOLEPSY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 153. GCC NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. GCC NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 155. GCC NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 156. GCC NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. GCC NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 158. GCC NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 159. GCC NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 160. GCC NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION NARCOLEPSY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 162. EUROPEAN UNION NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 163. EUROPEAN UNION NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 164. EUROPEAN UNION NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 165. EUROPEAN UNION NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. EUROPEAN UNION NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 167. EUROPEAN UNION NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 168. EUROPEAN UNION NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 169. EUROPEAN UNION NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS NARCOLEPSY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 173. BRICS NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 174. BRICS NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. BRICS NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 176. BRICS NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 177. BRICS NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 178. BRICS NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. G7 NARCOLEPSY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. G7 NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 181. G7 NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 182. G7 NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 183. G7 NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. G7 NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 185. G7 NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 186. G7 NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 187. G7 NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. NATO NARCOLEPSY DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. NATO NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. NATO NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 191. NATO NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 192. NATO NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. NATO NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 194. NATO NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 195. NATO NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 196. NATO NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. GLOBAL NARCOLEPSY DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 198. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 199. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 201. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 202. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 204. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 205. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 206. UNITED STATES NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. CANADA NARCOLEPSY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 208. CANADA NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 209. CANADA NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 210. CANADA NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 211. CANADA NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 212. CANADA NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 213. CANADA NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 214. CANADA NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 215. CANADA NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 216. MEXICO NARCOLEPSY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 217. MEXICO NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 218. MEXICO NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 219. MEXICO NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 220. MEXICO NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 221. MEXICO NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 222. MEXICO NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 223. MEXICO NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 224. MEXICO NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 225. BRAZIL NARCOLEPSY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 226. BRAZIL NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 227. BRAZIL NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 228. BRAZIL NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 229. BRAZIL NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. BRAZIL NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 231. BRAZIL NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 232. BRAZIL NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 233. BRAZIL NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED KINGDOM NARCOLEPSY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED KINGDOM NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED KINGDOM NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED KINGDOM NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED KINGDOM NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED KINGDOM NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED KINGDOM NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED KINGDOM NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED KINGDOM NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. GERMANY NARCOLEPSY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 244. GERMANY NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 245. GERMANY NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 246. GERMANY NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 247. GERMANY NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. GERMANY NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 249. GERMANY NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 250. GERMANY NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 251. GERMANY NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 252. FRANCE NARCOLEPSY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 253. FRANCE NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 254. FRANCE NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 255. FRANCE NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 256. FRANCE NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. FRANCE NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 258. FRANCE NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 259. FRANCE NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 260. FRANCE NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 261. RUSSIA NARCOLEPSY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 262. RUSSIA NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 263. RUSSIA NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 264. RUSSIA NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 265. RUSSIA NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 266. RUSSIA NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 267. RUSSIA NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 268. RUSSIA NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 269. RUSSIA NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 270. ITALY NARCOLEPSY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 271. ITALY NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 272. ITALY NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 273. ITALY NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 274. ITALY NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. ITALY NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 276. ITALY NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 277. ITALY NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 278. ITALY NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 279. SPAIN NARCOLEPSY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 280. SPAIN NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 281. SPAIN NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 282. SPAIN NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 283. SPAIN NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 284. SPAIN NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 285. SPAIN NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 286. SPAIN NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 287. SPAIN NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 288. CHINA NARCOLEPSY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 289. CHINA NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 290. CHINA NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 291. CHINA NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 292. CHINA NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 293. CHINA NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 294. CHINA NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 295. CHINA NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 296. CHINA NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 297. INDIA NARCOLEPSY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 298. INDIA NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 299. INDIA NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 300. INDIA NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 301. INDIA NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 302. INDIA NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 303. INDIA NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 304. INDIA NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 305. INDIA NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 306. JAPAN NARCOLEPSY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 307. JAPAN NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 308. JAPAN NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 309. JAPAN NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 310. JAPAN NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 311. JAPAN NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 312. JAPAN NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 313. JAPAN NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 314. JAPAN NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 315. AUSTRALIA NARCOLEPSY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 316. AUSTRALIA NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 317. AUSTRALIA NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 318. AUSTRALIA NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 319. AUSTRALIA NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 320. AUSTRALIA NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 321. AUSTRALIA NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 322. AUSTRALIA NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 323. AUSTRALIA NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 324. SOUTH KOREA NARCOLEPSY DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 325. SOUTH KOREA NARCOLEPSY DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 326. SOUTH KOREA NARCOLEPSY DRUGS MARKET SIZE, BY MODAFINIL DERIVATIVES, 2018-2032 (USD MILLION)
  • TABLE 327. SOUTH KOREA NARCOLEPSY DRUGS MARKET SIZE, BY NOVEL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 328. SOUTH KOREA NARCOLEPSY DRUGS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 329. SOUTH KOREA NARCOLEPSY DRUGS MARKET SIZE, BY PATIENT GROUP, 2018-2032 (USD MILLION)
  • TABLE 330. SOUTH KOREA NARCOLEPSY DRUGS MARKET SIZE, BY MECHANISM OF ACTION, 2018-2032 (USD MILLION)
  • TABLE 331. SOUTH KOREA NARCOLEPSY DRUGS MARKET SIZE, BY FORMULATION, 2018-2032 (USD MILLION)
  • TABLE 332. SOUTH KOREA NARCOLEPSY DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 333. GLOBAL NARCOLEPSY DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 334. GLOBAL NARCOLEPSY DRUGS MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025